Table 1.
Study characteristics of included studies.
| Author (Year) | Sample Size | Inclusion Criteria | Exclusion Criteria | Comparison Treatment | Age | Propranolol Treatment Dosage | Propranolol Treatment Duration | Follow-Up Time | Country | Year of Data Collection |
|---|---|---|---|---|---|---|---|---|---|---|
| Abrazua-Araya (2014) | 23 | IH needing treatment | History of allergy, hypersensitivity and treatment, heart or respiratory disease | Atenolol 1 mg/kg/d for 6 m | 5.2 ± 3.5 m | 2 mg/kg/d | 6 m | 0 m | Chile | 2012–2013 |
| Jin, YJ (2011) | 73 | Diagnosed with IH that influence their appearance were included. | Heart or respiratory disease | Prednisone 3 mg/kg/d, 6 m max | NR | 2 mg/kg/d | 6 m max | 0 m | China | 2009–2010 |
| Kim, K. H. (2017) | 34 | IH had 10–20% volume increase in 2–4 w or IH-related dysfunction or aesthetic problem | Without normal heart function or having treatment history | Prednisolone 2 mg/kg/d | 3.3 m | 2 mg/kg/d | 16 w | 4 w | Korea | 2013–2014 |
| Leaute-Labreze, C. (2013) | 14 | ≥ 1 nonthreatening IH > 1 cm; without vital or functional impairment; not justifying oral corticosteroids | Requiring urgent IH treatment; contraindications or history of treatment | Placebo | 12 w | 3–4 mg/kg/d | 1 m | 0 m | France | 2008–2010 |
| Malik, M. A. (2013) | 20 | Problematic IH | Presence or history of heart, bronchoobstructive, metabolic, or liver disease, visceral lesions, prematurity | Prednisolone 1 mg/kg/d | 4–5 m | 1–3 mg/kg/d | 1 y max | 6 m | India | 2011–2012 |
| Gong, H. (2015) | 26 | Superficial hemangiomas, no previous treatment | Deep/mixed haemangiomas, respiratory or heart disease, fever, diarrhea | 0.5% timolol maleate eye drops | NR | 1.5 mg/kg/d | 5.3 m | 3–12 m | China | 2012–2013 |
| Zhong S (2015) | 40 | Mixed or deeper IH >8 mm diameter, treatment naïve; complete treatment and follow-up | Heart and respiratory disease | Laser | 3.69 m | 1.5 mg/kg/d | 6 m | 0 m | China | 2013–2014 |
| Bauman (2014) | 19 | Proliferating and symptomatic IH | Inadequate social support, received other IH treatment for IH, having a co-morbidity | Prednisolone 2 mg/kg/d | 2.5–4 m | 2 mg/kg/d | 323 d average | 0 m | US | 2010–2012 |
| Hogeling, M. (2011) | 39 | IHs with a deep component, impair function, or aesthetic disfigurement, late or failed to respond to corticosteroid therapy. | Requiring urgent treatment, contraindications to propranolol, extracutaneous IH | Placebo | 67–71 w | 1–2 mg/kg/d | 6.5 m | 0 m | Australia | 2009–2010 |
| Leaute-Labreze, C. (2015) | 456 | A proliferating IH required systematic therapy | Patients with life-threatening, function-threatening, or severely ulcerated hemangiomas | Placebo | 103.8 d | 1–3 mg/kg/d | 3 or 6 m | 72 w | Multiple | 2010–2011 |
| Tan, M. (2012) | 97 | IH diagnosis, treatment naïve | Respiratory, cardiovascular diseases, other systematic chronic diseases | Laser | NR | 0.5–1 mg/kg/d | 6 m | 0 m | China | 2010–2011 |